These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9873600)

  • 1. Thalidomide analogs and PDE4 inhibition.
    Muller GW; Shire MG; Wong LM; Corral LG; Patterson RT; Chen Y; Stirling DI
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2669-74. PubMed ID: 9873600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors.
    Ducharme Y; Friesen RW; Blouin M; Côté B; Dubé D; Ethier D; Frenette R; Laliberté F; Mancini JA; Masson P; Styhler A; Young RN; Girard Y
    Bioorg Med Chem Lett; 2003 Jun; 13(11):1923-6. PubMed ID: 12749899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and structure-activity relationships of a series of 9-substituted adenine derivatives as selective phosphodiesterase type-4 inhibitors.
    Raboisson P; Lugnier C; Muller C; Reimund JM; Schultz D; Pinna G; Le Bec A; Basaran H; Desaubry L; Gaudiot F; Seloum M; Bourguignon JJ
    Eur J Med Chem; 2003 Feb; 38(2):199-214. PubMed ID: 12620664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF-alpha properties of new 9-benzyladenine derivatives with selective phosphodiesterase-4- inhibiting properties.
    Reimund JM; Raboisson P; Pinna G; Lugnier C; Bourguignon JJ; Muller CD
    Biochem Biophys Res Commun; 2001 Oct; 288(2):427-34. PubMed ID: 11606060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
    Kleinman EF; Campbell E; Giordano LA; Cohan VL; Jenkinson TH; Cheng JB; Shirley JT; Pettipher ER; Salter ED; Hibbs TA; DiCapua FM; Bordner J
    J Med Chem; 1998 Jan; 41(3):266-70. PubMed ID: 9464356
    [No Abstract]   [Full Text] [Related]  

  • 6. Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors.
    Ukita T; Sugahara M; Terakawa Y; Kuroda T; Wada K; Nakata A; Kikkawa H; Ikezawa K; Naito K
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2347-50. PubMed ID: 12824031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and structure-activity relationship of N-arylrolipram derivatives as inhibitors of PDE4 isozymes.
    Keller TH; Bray-French K; Demnitz FW; Müller T; Pombo-Villar E; Walker C
    Chem Pharm Bull (Tokyo); 2001 Aug; 49(8):1009-17. PubMed ID: 11515569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues.
    Prehn JL; Landers C; Muller GW; Man HW; Stirling DI; Targan SR
    J Clin Immunol; 2001 Sep; 21(5):357-64. PubMed ID: 11720008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Substituted furans as inhibitors of the PDE4 enzyme.
    Perrier H; Bayly C; Laliberté F; Huang Z; Rasori R; Robichaud A; Girard Y; Macdonald D
    Bioorg Med Chem Lett; 1999 Feb; 9(3):323-6. PubMed ID: 10091677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors.
    Muise ES; Chute IC; Claveau D; Masson P; Boulet L; Tkalec L; Pon DJ; Girard Y; Frenette R; Mancini JA
    Biochem Pharmacol; 2002 Apr; 63(8):1527-35. PubMed ID: 11996895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles.
    Hulme C; Poli GB; Huang FC; Souness JE; Djuric SW
    Bioorg Med Chem Lett; 1998 Jan; 8(2):175-8. PubMed ID: 9871649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derived from 9-benzyladenine.
    Boichot E; Wallace JL; Germain N; Corbel M; Lugnier C; Lagente V; Bourguignon JJ
    J Pharmacol Exp Ther; 2000 Feb; 292(2):647-53. PubMed ID: 10640302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly potent PDE4 inhibitors with therapeutic potential.
    Ochiai H; Ohtani T; Ishida A; Kusumi K; Kato M; Kohno H; Kishikawa K; Obata T; Nakai H; Toda M
    Bioorg Med Chem Lett; 2004 Jan; 14(1):207-10. PubMed ID: 14684329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
    Burnouf C; Auclair E; Avenel N; Bertin B; Bigot C; Calvet A; Chan K; Durand C; Fasquelle V; Féru F; Gilbertsen R; Jacobelli H; Kebsi A; Lallier E; Maignel J; Martin B; Milano S; Ouagued M; Pascal Y; Pruniaux MP; Puaud J; Rocher MN; Terrasse C; Wrigglesworth R; Doherty AM
    J Med Chem; 2000 Dec; 43(25):4850-67. PubMed ID: 11123995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
    Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinazolines: combined type 3 and 4 phosphodiesterase inhibitors.
    Charpiot B; Brun J; Donze I; Naef R; Stefani M; Mueller T
    Bioorg Med Chem Lett; 1998 Oct; 8(20):2891-6. PubMed ID: 9873643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues.
    Lima LM; Castro P; Machado AL; Fraga CA; Lugnier C; de Moraes VL; Barreiro EJ
    Bioorg Med Chem; 2002 Sep; 10(9):3067-73. PubMed ID: 12110331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.
    Manning CD; Burman M; Christensen SB; Cieslinski LB; Essayan DM; Grous M; Torphy TJ; Barnette MS
    Br J Pharmacol; 1999 Dec; 128(7):1393-8. PubMed ID: 10602317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
    Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ
    Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orally active indole N-oxide PDE4 inhibitors.
    Hulme C; Mathew R; Moriarty K; Miller B; Ramanjulu M; Cox P; Souness J; Page KM; Uhl J; Travis J; Labaudiniere R; Huang F; Djuric SW
    Bioorg Med Chem Lett; 1998 Nov; 8(21):3053-8. PubMed ID: 9873675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.